Target / Biomarker
Discovery & Validation
Euretos is an AI (Artificial Intelligence) platform used by pre-clinical researchers for in-silico discovery & validation of targets and biomarkers. World leading pharma, biotech and academic institutions use it to accelerate their research. Available as subscription, consulting service or direct access
EURETOS AI PLATFORM
In Silico Multi Omics
Drive your in vitro and in vivo research by in silico multi omics analysis. Ask Euretos and evaluate how molecular mechanisms influence cell and tissue functions, and in turn mediate phenotypes and disease pathology.
FIND OUT MORE
Researchers use Euretos AI Platform data for machine learning model that predicts outcome of clinical trials with 92% accuracySunday 28 April 2019
In a recent publication in Nature Scientific Reports researchers at the Leiden and Rotterdam medical universities have used Euretos AI Platform data to train a machine learning model that predicts with 92.2% accuracy whether a drug will be successf ...
Public-private consortium including Euretos, wins highly contested grant for rare disease drug repurposingMonday 04 February 2019
A public-private consortium, including Euretos, recently won a very competitive grant (with about 10% success rate) from the E-Rare European Research Area Programme. The grant was awarded for a drug repurposing project for Myotonic dystrophy type 1 ...
Prof David Webb (The Scripps Research Institute)
“The Euretos AI Platform is nothing less than an in silico way to save all drug and biotech researchers an infinite amount of blood, sweat and tears by providing
them with a powerful knowledge discovery platform.
The Euretos AI Platform allows the researcher to rapidly assess whether a given target, research area, etc., is related, even distantly, to another such entity thus allowing one to uncover hidden connections, leading to new knowledge.In the drug discovery arena, this thing is a gold mine.